MDSpire - MDSpire Home
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

The Pathologist

  • November 3, 2026
ASCP 2026: Mentoring Across International Borders
  • November 3, 2026
  • 3 min
  1. Mohamed Abdelmonem and Marion Carrillo preview 2 interactive round tables at the ASCP Annual Meeting in November in Montréal.
  2. One round table will discuss how ASCP can make global membership more valuable, accessible, and relevant to international members.
  3. Speakers cite finances, education access, language, technology, professional recognition, local regulations, and health care system differences as participation barriers.
  4. The mentorship discussion will address cultural responsiveness, language, professional expectations, career pathways, and differences in laboratory medicine across countries.
  5. The sessions will use discussion, real-world examples, audience polling, and open dialogue to identify challenges and develop practical solutions.
...more

The Pathologist

  • November 3, 2026
Prognostic Biomarkers for Chagas Disease
  • November 3, 2026
  • 2 min

Objective: To identify blood metabolites associated with future cardiac disease progression in people with chronic Chagas disease. Approach: Study samples: Rese

...more
1 min

The Analytical Scientist

  • November 3, 2026
The Big Challenges: Part One – People, Resources, Reach
  • November 3, 2026
  • 11 min

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

Take the Quiz

The Analytical Scientist

  • November 3, 2026
A New Interface for Longer-Lasting Batteries
  • November 3, 2026
  • 3 min
  1. Researchers coated a three-dimensional nanotubular copper current collector with an approximately 10-nm layer of Ti₃C₂Tₓ MXene for anode-free lithium-metal batteries.
  2. The MXene coating interacted with electrolyte hexafluorophosphate anions and promoted uniform lithium nucleation and a lithium fluoride-rich solid-electrolyte interphase.
  3. X-ray photoelectron spectroscopy, time-of-flight secondary ion mass spectrometry, and transmission electron microscopy characterized the interface and showed lithium fluoride nanoparticles along the M
  4. In lean-electrolyte coin cells with NCM811 cathodes, modified collectors retained 78.1 mAh/g at cycle 125, compared with 44.9 mAh/g for unmodified copper.
  5. At cycle 125, Coulombic efficiency was 99.06% with the modified collector and 95.01% with unmodified copper; larger-format testing remains necessary to assess commercial performance.
...more

The Analytical Scientist

  • November 3, 2026
Last Orders for Drug Residues?
  • November 3, 2026
  • 3 min

Objective: Assess whether atmospheric pressure solids analysis probe mass spectrometry (ASAP-MS) can rapidly screen surfaces for illicit drug residues, compared

...more

MDSpire News

  • November 3, 2026
May long COVID improve without full recovery?
  • Andrea Surnit
  • November 3, 2026
  • 4 min

Objective: To estimate how often adults with likely long COVID improve or achieve complete symptom resolution over time. Approach: Study design: Prospective obs

...more
2 min

MDSpire News

  • November 3, 2026
Can patient factors identify who benefits from fusion?
  • Andrea Surnit
  • November 3, 2026
  • 4 min

Objective: To assess whether adding fusion to decompression improves 12-month outcomes for patients with degenerative lumbar spondylolisthesis and whether patie

...more
2 min

MDSpire News

  • November 3, 2026
Rosacea and IBS show bidirectional association
  • Andrea Surnit
  • November 3, 2026
  • 4 min

Objective: To assess whether rosacea is associated with subsequent irritable bowel syndrome (IBS), and whether IBS is associated with subsequent rosacea. Approa

...more
2 min

MDSpire News

  • November 3, 2026
FDA tentatively approves generic lenacapavir
  • Mouj Hijazi
  • November 3, 2026
  • 3 min

Objective: The article examines the objective, findings, and clinical context described in FDA tentatively approves generic lenacapavir. Approach: Regulatory st

...more

The Medicine Maker

  • November 3, 2026
America Votes, China Plans
  • James Strachan
  • November 3, 2026
  • 26 min

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

Take the Quiz

The Medicine Maker

  • November 3, 2026
Can Immunopeptidomics Redefine Cancer Immunotherapy Development?
  • Katherine Tran
  • November 3, 2026
  • 4 min

Objective: The article examines the objective, findings, and clinical context described in Can Immunopeptidomics Redefine Cancer Immunotherapy Development?. App

...more
2 min

The Medicine Maker

  • November 3, 2026
BMS Details Patient Death in Zola-Cel Multiple Sclerosis Trial
  • November 3, 2026
  • 3 min

Objective: The article examines the objective, findings, and clinical context described in BMS Details Patient Death in Zola-Cel Multiple Sclerosis Trial. Appro

...more

Infection

  • November 3, 2026
Leptospirosis as a recurring indicator of climate change and urban health inequities
  • Julio C. Valencia Manrique
  • Abigail Young
  • Emily Carson
  • Jennifer Harley
  • November 3, 2026

Objective: Present a case of severe, PCR-confirmed leptospirosis in a homeless man and discuss the disease’s urban epidemiology in relation to climate condition

...more
3 min

Kaiser Family Foundation

  • November 3, 2026
How Europe’s Largest Hospital Is Developing AI Internally
  • kffrobins
  • November 3, 2026
  1. Charité – Universitätsmedizin Berlin is developing its own AI rather than relying primarily on purchased systems.
  2. The hospital consolidated previously dispersed AI initiatives within its Institute for Artificial Intelligence in Medicine.
  3. Charité activated Clé, an internally developed platform spanning research, teaching, patient care, and administration.
  4. CEO Heyo Kroemer said AI’s success depends on improving care, assisting staff, and making innovation practical for routine work.
  5. The episode examines the potential gains and risks of owning an AI platform rather than licensing one.
...more

The Pathologist

  • November 3, 2026
High-Sensitivity ESR1 Detection by Digital PCR in Metastatic Breast Cancer Research Samples: From Analytical Validation to Potential Clinical Applications
  • November 3, 2026
  • 3 min

Objective: To review the clinical relevance of ESR1 mutations and the role of digital PCR in high-sensitivity ctDNA analysis for metastatic breast cancer. Appro

...more

MDSpire News

  • November 2, 2026
FDA approves HPV immunotherapy for RRP
  • Mouj Hijazi
  • November 2, 2026
  • 3 min

Objective: The article examines the objective, findings, and clinical context described in FDA approves HPV immunotherapy for RRP. Approach: Approval: The FDA g

...more
2 min

MDSpire News

  • November 2, 2026
Does corneal structure remain stable after 10 years of contact lenses?
  • Andrea Surnit
  • November 2, 2026
  • 4 min

Objective: Compare corneal structure and endothelial characteristics in young adults with more than 10 years of childhood daily disposable hydrogel contact lens

...more
2 min

MDSpire News

  • November 2, 2026
RA drug tapering may match standard dosing
  • Andrea Surnit
  • November 2, 2026
  • 5 min
  1. In the RESTORE-RA trial, structured tapering of biologic or targeted synthetic DMARDs was noninferior to standard dosing for maintaining low disease activity at 24 weeks.
  2. Low disease activity was maintained by 88.2% of patients assigned to tapering and 89.6% assigned to continued treatment in the per-protocol analysis.
  3. Some secondary disease activity measures favored continued treatment, although patient-reported disease activity and quality-of-life measures did not differ significantly.
  4. Among 23 tapering-group patients who lost low disease activity by week 12, 17 regained it by week 24 after treatment reescalation.
  5. Exploratory analyses found lower low-disease-activity maintenance with tapered JAK inhibitors than with continued JAK inhibitors, but were not powered to establish drug-class noninferiority.
...more